[1] Tang R,Xia DS,Tian CH,et al.Stage Characteristic of Pprescription and Nonprescription Switch in China[J]. Chinese Journal of Pharmacovigilance(中国药物警戒),2013,10(5):278-282. [2] National Medical Products Administration. Provisions of Pprescription and Nonprescription [EB/OL].(1999-06-18)[2020-02-26].http://www.nmpa.gov.cn/WS04/CL2196/323452.html. [3] National Medical Products Administration. Notice on Evaluation of Pprescription and Nonprescription Switch [EB/OL].(2004-04-07) [2020-02-26].http://www.nmpa.gov.cn/WS04/CL2196/323452.html. [4] National Medical Products Administration. Notice on Evaluation of Pprescription Switch to Nonprescription [EB/OL].(2010-06-30) [2020-02-26].http://www.nmpa.gov.cn/WS04/CL2196/323778.html. [5] National Medical Products Administration.Notice on the issuance of 6 guidelines for prescription and Nonprescription Switch [EB/OL]. (2012-11-14)[2020-02-26].http://www.nmpa.gov.cn/WS04/CL2196/323939.html. [6] Cao MD,Wu Y,Wang Z,et al.Characteristics of Chinese Traditional Patent Medicines Approved for MAarketing in China[J]. Chinese Traditional Ppatent Mmedicine,2019,41(8):1999-2006. [7] National Medical Products Administration. publication of the non-prescription drugs labels [EB/OL].(2007-02-01)[2020-02-26]. http://www.nmpa.gov.cn/WS04/CL2115/286564.html. [8] Hang XP,Sun WD,Zhang XP.The Research of OTC Drugs'instructions in China[J].Medicine and Society,2011,24(8):50-52,56. [9] Wang XF,Wei Q,Luo YJ, et al.Analysis of prescription and non-prescription drug instructions of Chinese patent medicine[J]. Chinese Traditional Ppatent Mmedicine,2019,41(8):2022-2024. [10] Xia DS,Tian CH,Wang A, et al.The Pprobe into the Necessity of the Safety Monitoring of Over-The-Counter Drug in China[J]. Chinese Journal of Pharmacovigilance,2013,10(2):80-83. [11] Zheng MJ, Xia DS.Problem Analysis and Suggestion on Application Materials of OTC Switch[J]. Chinese Journal of Pharmacovigilance, 2015,12(10):618-622. [12] Wang D,Li XL,Dong D, et al.Investigation of Pharmaceutical Manufacturers' Ability of Direct Reporting of Drug Adverse Reactions[J]. Chinese Journal of Pharmacovigilance,2019,16(11): 654-661. [13] National Medical Products Administration. Annual Report for National ADR Monitoring(2018) [EB/OL].(2019-10-18)[2020-02-26].http://www.nmpa.gov.cn/WS04/CL2138/359373.html. [14] Hou YF, Liu HL, Zheng MJ.Direct Reporting System for Adverse Drug Reactions Strengthens Fulfillment of Responsibilities of Marketing Authorization Holders[J]. Chinese Journal of Pharmaco vigilance,2019,16(11):662-665. [15] Xia DS.Discussion on Rational Use of Non-prescription Drugs and Adverse Reactions Avoidance Strategy[J]. Chinese Journal of Pharmacovigilance,2010,7(6):343-346. |